Preclinical Evaluation of an mRNA Vaccine Developed from the First Human Isolate of Bovine H5N1

Hongli Li, Mengting Huang, Simin Feng, Wansheng Li, Dandan Wei, Xuechun Li, Lin‐Lei Chen, Yun Quan, Hao Gu, Ting Jiang, Yan Liu, Jing Lu, Wenjun Song, Xuan Zhang, Yujia Yang, Qiu Pan, Jingyou Yu, Hantao Lou, Mingjie Zhang, Youchun Wang, Kelvin Kai‐Wang To, Weixin Jia, Jinzhong Lin, Qiong ZhangSSRN 2025 · DOI

Introduction

The emergence of Highly Pathogenic Avian Influenza (HPAI) H5N1 in U.S. dairy cattle in early 2024 represents a significant shift in the virus's ecology and pandemic potential. The subsequent documentation of bovine-to-human transmission via the A/Texas/37/2024 strain has heightened global health concerns. Current H5N1 vaccine candidates, primarily based on older clades like Ast20, face challenges due to antigenic drift—specifically mutations such as L115Q found in the Texas isolate that facilitate antibody escape. This study details the development of a matched mRNA-LNP vaccine designed to provide robust, broad-spectrum protection against this emerging threat.

Methodology

Researchers utilized a nucleoside-modified mRNA platform encapsulated in lipid nanoparticles (LNPs), similar to the technology used in successful COVID-19 vaccines. Two variants of the Hemagglutinin (HA) protein from the A/Texas/37/2024 strain were synthesized: a wild-type (WT) version and a cleavage-defective mutant (Mut). The Mut variant featured a modified polybasic cleavage site to enhance protein stability and safety during production.

Delivery was evaluated using both the industry-standard SM102 lipid and a novel ionizable lipid, LQ-016-DB-Y (DB-Y). The vaccine's performance was assessed across multiple animal models:

  • BALB/c mice for immunogenicity and lethal challenge.
  • SPF chickens to evaluate protection in poultry populations.
  • Sprague-Dawley rats for formal toxicological safety assessment.

Immune responses were quantified using ELISA for binding antibodies, microneutralization (MN) assays for functional antibodies, and T-cell profiling via ELISpot and flow cytometry.

Results and Discussion

Immunogenicity and Protective Efficacy

The mRNA-LNP vaccine demonstrated exceptional potency. In lethal challenge models, 100% of vaccinated mice and chickens survived exposure to H5 viruses. Notably, the "Mut" HA variant elicited immune responses comparable to the WT version while offering superior stability. Neutralizing antibody titers remained significantly elevated for over eight months in murine models, suggesting long-term durability that could be critical in a pandemic scenario.

Cross-Clade Breadth and Antigenic Priming

A critical finding was the vaccine's broad-spectrum activity. The Texas-matched vaccine provided superior cross-protection against a panel of heterologous H5 strains (including Clades 1, 2.1.3.2, 2.2, 2.3.2.1a, and 2.3.4.4b/h) compared to the WHO-recommended Ast20 strain. Furthermore, the study addressed the concern of "original antigenic sin" by demonstrating that pre-existing immunity to seasonal H1N1 influenza did not impair the immune response to the H5 vaccine; H1-primed mice achieved full protection upon H5 challenge.

Innovation in Delivery and Safety

The novel DB-Y lipid showed high efficacy, outperforming SM102 in in vivo luciferase expression assays, marking it as a viable candidate for future LNP formulations. Toxicology studies in rats indicated a favorable safety profile, with only transient local inflammation and expected, temporary systemic immune activation (such as brief drops in white blood cell counts), without evidence of chronic organ toxicity.

Conclusion

This preclinical evaluation confirms that a matched mRNA-LNP vaccine targeting the A/Texas/37/2024 strain is highly effective, durable, and capable of overcoming existing seasonal immunity. While biosafety restrictions necessitated the use of a surrogate challenge strain (98% identical to the Texas isolate), the results strongly support the rapid deployment of this platform in response to H5N1 spillover events. Future research will focus on evaluating mucosal immunity via intranasal delivery and initiating clinical validation in humans.

Summary updated

BibTeX
@misc{li2025preclinical,
  author = {Hongli Li and Mengting Huang and Simin Feng and Wansheng Li and Dandan Wei and Xuechun Li and Lin‐Lei Chen and Yun Quan and Hao Gu and Ting Jiang and Yan Liu and Jing Lu and Wenjun Song and Xuan Zhang and Yujia Yang and Qiu Pan and Jingyou Yu and Hantao Lou and Mingjie Zhang and Youchun Wang and Kelvin Kai‐Wang To and Weixin Jia and Jinzhong Lin and Qiong Zhang},
  title = {{Preclinical Evaluation of an mRNA Vaccine Developed from the First Human Isolate of Bovine H5N1}},
  year = {2025},
  doi = {10.2139/ssrn.5353082},
  howpublished = {SSRN},
}
Figure